ITT
|
Months post HDM/SCT
|
---|
3
|
3
|
12
|
12
|
24
|
24
|
---|
BD + HDM/SCT
|
HDM/SCT
|
BD + HDM/SCT
|
HDM/SCT
|
BD + HDM/SCT
|
HDM/SCT
|
---|
|
Number = 28
|
Number = 28
|
Number = 28
|
Number = 28
|
Number = 20
|
Number = 23
|
---|
CR
|
15 (53.6%)a
|
6 (21.4%)
|
19 (67.9%)a
|
10 (35.7%)
|
14 (70%)a
|
8 (34.8%)
|
VGPR
|
4 (14.3%)
|
4 (14.3%)
|
2 (7.1%)
|
3 (10.7%)
|
1 (5%)
|
1(4.3%)
|
PR
|
3 (10.7%)
|
4 (14.3%)
|
3 (10.7%)
|
2(2.1%)
|
1 (5%)
|
2 (8.7%)
|
NR
|
6 (21.4%)
|
12 (42.8%)
|
2 (7.1%)
|
6 (21.4%)
|
2 (10%)
|
3 (13.0%)
|
PD
|
-
|
-
|
2 (7.1%)
|
3 (10.7%)
|
1 (5%)
|
3 (13.0%)
|
Organ responses
|
Kidneyb
| | |
65.2% (15/23)
|
39.1% (9/23)
|
75% (12/16)
|
53.8% (7/13)
|
Heartb
| | |
67% (10/15)
|
25% (4/12)
|
70% (7/10)
|
50% (3/6)
|
Liverb
| | |
100% (1/1)
|
50% (1/2)
|
100% (1/1)
|
100% (1/1)
|
NSb
| | |
100% (3/3)
|
100% (2/2)
|
100% (3/3)
|
100% (2/2)
|
-
aCompared with the HDM/SCT group, P <0.05; bevaluable patients. CR, complete hematological response; ITT, intention-to-treat; NR, no response; NS, nervous system; PD, disease progression; PR, partial response; SD, stable disease; VGPR, very good partial response.